PJP vs THNR
Invesco Pharmaceuticals ETF against Amplify Weight Loss Drug & Treatment ETF: cost, size, returns, what they hold and how much of it is the same.
Overlap by weight
27%
6 shared positions
Fee gap
2 bp
PJP is cheaper
1-year return gap
29.9 pts
PJP is ahead
Larger fund
PJP
$555M
Side by side
| PJP | THNR | |
|---|---|---|
| Fund | Invesco Pharmaceuticals ETF | Amplify Weight Loss Drug & Treatment ETF |
| Issuer | Invesco | Amplify |
| Category | Health Care | Global |
| Expense ratio | 0.57% | 0.59% |
| Assets | $555M | $5.6M |
| Average daily dollar volume | $5.1M | $18K |
| Listed | Jun 23, 2005 | May 20, 2024 |
| FrenzyCap score | 49 | 22 |
| 1-month return | −1.5% | −4.6% |
| 3-month return | +4.5% | −4.4% |
| Year to date | +17.5% | −2.8% |
| 1-year return | +29.5% | −0.4% |
| 30-day volatility | 15.8% | 19.2% |
| Worst drawdown, 1 year | −9.7% | −13.1% |
| Trailing 12-month yield | 0.92% | 1.69% |
| Holdings | 31 | 21 |
| Top 10 weight | 50.2% | 60.2% |
| Look-through P/E | 428.7 | — |
| Holdings vs fair value | +10.7% | −1.7% |
| Holdings above 200-day average | 77% | 59% |
| Net flow, latest 3 reported months | +$86M thru Jul 2026 | $0 thru Jun 2026 |
| 30-day implied volatility | 17.9% | — |
| Holdings as of | as of Oct 8, 2026issuer data | as of Jun 30, 2026SEC filing |
Returns are price returns and exclude distributions. Flows are each fund's own latest reported months and may not cover the same period.
Largest shared holdings
30% of PJP · 32% of THNR
Sector mix of the stock holdings
| Sector | PJP | THNR | Gap |
|---|---|---|---|
| Health Care | 99.9% | 66.5% | +33.4% |
More: full overlap table · PJP holdings · THNR holdings
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.